John M. Vierling MD , FACP, FAASLD, AGAF
Hepatology & Liver Transplantation
Professor of Medicine and Surgery; Chief of Hepatology; Director of Advanced Liver Therapies. Baylor College of Medicine
Join to view full profile
6620 Main StHouston, TX 77030
Phone+1 713-798-2500
Fax+1 713-798-2505
Dr. Vierling is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. John Vierling is a gastroenterologist in Houston, TX and is affiliated with Baylor St. Luke's Medical Center. He received his medical degree from Stanford University School of Medicine and has been in practice 45 years. He specializes in hepatology & liver transplantation and is experienced in general gastroenterology, hepatology, transplant hepatology, and biliary tract disease.
Education & Training
University of California (San Francisco)Fellowship, Gastroenterology, 1977 - 1978
National Institutes of HealthNone, USPHS Surg-04; Clinical Associate, Liver Unit, 1974 - 1977
University of Rochester Medical CenterResidency, Internal Medicine, 1972 - 1974
Stanford University School of MedicineClass of 1972
Certifications & Licensure
CA State Medical License 1975 - 2027
TX State Medical License 2007 - 2027
CO State Medical License 1979 - 1993
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Who's Who in the World Marquis, 2015-2023
- America's Top Doctors Castle Connolly, 2002-2023
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011, 2013-2014
Clinical Trials
Publications & Presentations
PubMed
- Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.Stuart C Gordon, Alejandra Villamil, Ira M Jacobson, Eric J Lawitz, Ziad Younes
Hepatology Communications. 2026-05-01 - 2 citationsThe ethics of unlicensed therapy use in primary biliary cholangitis: a counter view.David E J Jones, Robert Mitchell-Thain, Emma L Culver, Jessica K Dyson, Robert G Gish
Nature Reviews. Gastroenterology & Hepatology. 2026-04-01 - 1 citationsMultiscale zonation-resolved modeling of dose-dependent determinants of acetaminophen-induced liver injury.Debarshi Ghosh, Stelian Camara Dit Pinto, Alon Malka-Markovitz, Mohammed Cherkaoui, Reza Sadeghi
Frontiers in Pharmacology. 2026-01-01
Journal Articles
- Trends in Outcomes for Marginal Allografts in Liver TransplantJohn M Vierling, Abbas Rana, JAMA Surgery
Other
- Overview of immunosuppression in adult liver transplantationVierling JM, Sussman NL
http://www.uptodate.com/contents/overview-of-immunosuppression-in-adult-liver-transplantation
UpToDate, Wolters Kluwer Health - 2013-03-12
Press Mentions
Can Ramadan Fasting Hold the Key to Improved Health? A Houston Doctor Aims to Find OutMay 12th, 2020
Baylor College of Medicine Is Experimenting with AI to Improve Liver Transplant OutcomesAugust 2nd, 2019
Athenex Announces Expansion of Board of DirectorsMarch 21st, 2019
Grant Support
- Hepatic Lesions In Murine Chronic Graft VS Host DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2001
- Hepatic Lesions In Murine Chronic Graft-Vs-Host DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases1989–1991
- Hepatic Lesions In Murine Chronic Graft-Vs-Host DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases1986–1989
Professional Memberships
- Member
- Member
- American Association for the Study of Liver DiseasesFellow
- Fellow
- European Association for the Study of LiverMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: